A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).Andrew L. Coveler, T.R. Jeffry Evans, Lisa Rodgers et al.|Journal of Clinical Oncology|2021Cited by 6
354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)Andrew L. Coveler, T. R. J. Evans, Aglaia Skolariki et al.|Annals of Oncology|2022Cited by 3
Abstract CT136: NUC-7738, a novel ProTide transformation of 3′-deoxyadenosine, in patients with advanced solid tumorsRuth Plummer, Sarah P. Blagden, Francesca Aroldi et al.|Cancer Research|2021Cited by 2
Abstract CT140: NUC-3373, a targeted inhibitor of thymidylate synthase, in patients with advanced colorectal cancerFarasat Kazmi, TR Jeffry Evans, Jordan Berlin et al.|Cancer Research|2021Cited by 2
475P A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302)Jordan Berlin, Sarah P. Blagden, Mary Linton B. Peters et al.|Annals of Oncology|2021Cited by 1